A detailed history of Invesco Ltd. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 56,412 shares of RVNC stock, worth $144,978. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,412
Previous 62,683 10.0%
Holding current value
$144,978
Previous $161,000 10.56%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.57 - $2.57 $16,116 - $16,116
-6,271 Reduced 10.0%
56,412 $144,000
Q2 2024

Aug 13, 2024

BUY
$2.34 - $4.73 $27,492 - $55,572
11,749 Added 23.07%
62,683 $161,000
Q1 2024

May 14, 2024

SELL
$4.65 - $9.31 $7.22 Million - $14.4 Million
-1,551,688 Reduced 96.82%
50,934 $250,000
Q4 2023

Feb 12, 2024

SELL
$5.81 - $11.2 $7.55 Million - $14.6 Million
-1,299,818 Reduced 44.78%
1,602,622 $14.1 Million
Q3 2023

Nov 13, 2023

BUY
$11.47 - $25.07 $13.2 Million - $28.9 Million
1,153,615 Added 65.97%
2,902,440 $33.3 Million
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $37.7 Million - $57.4 Million
1,527,259 Added 689.3%
1,748,825 $44.3 Million
Q1 2023

May 12, 2023

BUY
$18.36 - $35.27 $2.85 Million - $5.47 Million
155,131 Added 233.51%
221,566 $7.14 Million
Q4 2022

Feb 13, 2023

SELL
$18.32 - $30.66 $3.19 Million - $5.34 Million
-174,255 Reduced 72.4%
66,435 $1.23 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $2.55 Million - $5.06 Million
177,802 Added 282.73%
240,690 $6.5 Million
Q2 2022

Aug 15, 2022

SELL
$11.52 - $20.4 $1.79 Million - $3.17 Million
-155,458 Reduced 71.2%
62,888 $869,000
Q1 2022

May 16, 2022

BUY
$12.36 - $20.31 $2.21 Million - $3.63 Million
178,955 Added 454.3%
218,346 $4.26 Million
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $33,430 - $74,775
-2,683 Reduced 6.38%
39,391 $643,000
Q3 2021

Nov 15, 2021

BUY
$25.78 - $33.21 $138,619 - $178,570
5,377 Added 14.65%
42,074 $1.17 Million
Q2 2021

Aug 17, 2021

BUY
$26.8 - $31.84 $268,321 - $318,782
10,012 Added 37.52%
36,697 $1.09 Million
Q1 2021

May 17, 2021

BUY
$24.03 - $29.97 $304,339 - $379,570
12,665 Added 90.34%
26,685 $746,000
Q4 2020

Feb 16, 2021

SELL
$23.41 - $28.34 $513,732 - $621,921
-21,945 Reduced 61.02%
14,020 $398,000
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $99,610 - $147,078
4,288 Added 13.54%
35,965 $904,000
Q2 2020

Aug 14, 2020

BUY
$12.6 - $26.55 $399,130 - $841,024
31,677 New
31,677 $773,000
Q1 2020

May 15, 2020

SELL
$12.46 - $27.81 $147,850 - $329,993
-11,866 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$11.66 - $20.15 $8,954 - $15,475
-768 Reduced 6.08%
11,866 $193,000
Q3 2019

Nov 14, 2019

SELL
$10.22 - $14.5 $5,028 - $7,134
-492 Reduced 3.75%
12,634 $164,000
Q2 2019

Aug 14, 2019

SELL
$10.67 - $15.49 $63,817 - $92,645
-5,981 Reduced 31.3%
13,126 $170,000
Q1 2019

May 15, 2019

BUY
$15.4 - $20.39 $294,247 - $389,591
19,107 New
19,107 $301,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.